ArticleIJTLD open2026
Fluoroquinolones for TB preventive treatment of contacts exposed to persons with multidrug-resistant TB: a systematic review and meta-analysis.
Article in IJTLD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe evaluated the safety, acceptability, and cost-effectiveness of all published studies on fluoroquinolone (FQ)-based TB preventive treatment (TPT) regimens in all settings and populations.
methodsWe searched for studies published between February 2014 and September 2023 using PubMed, Embase, Turning Research Into Practice (TRIP), Global Health Library, and the Cochrane Central Register of Controlled Trials. Meta-analysis was conducted using random effects models.
resultsTwenty-two observational and modelling studies evaluating FQ-based TPT were included, assessing outcomes of safety (n = 16), acceptability (n = 9), and cost-effectiveness (n = 2). Only 2% (95% confidence interval [CI]: 0%-4%) of children and adolescents and 8% (95% CI: 2%-14%) of adults discontinued FQ monotherapy due to drug-related adverse events (AEs). Compared to FQ monotherapy, rates of drug-related AEs of any severity were non-significantly higher with multidrug FQ regimens without pyrazinamide (PZA). Pooled discontinuation rates were 50% (95% CI: 34%-67%) among children and 57% (95% CI: 16%-98%) among adult contacts treated with PZA-containing FQ-based regimens. Pooled acceptance rates exceeded 80% among all groups. FQ-based TPT was cost-effective to avert TB-related deaths and loss of quality-adjusted life-years.
conclusionThese results complement the evidence from two recent randomised trials. FQ monotherapy is a safe, acceptable, and cost-effective TPT regimen for contacts exposed to multidrug-resistant or rifampicin-resistant TB disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.